Candidate serum metabolite biomarkers for differentiating gastroesophageal reflux disease, Barrett’s esophagus, and high-grade dysplasia/esophageal adenocarcinoma
暂无分享,去创建一个
Daniel Raftery | Jiangjiang Zhu | Thomas L. Vaughan | Danijel Djukovic | Brian J. Reid | Haiwei Gu | B. Reid | T. Vaughan | D. Raftery | Jiangjiang Zhu | Haiwei Gu | Danijel Djukovic | Lynn Onstad | L. Onstad | Matthew F. Buas
[1] Kamran Ayub,et al. NSAIDs Modulate CDKN2A, TP53, and DNA Content Risk for Progression to Esophageal Adenocarcinoma , 2007, PLoS medicine.
[2] N. Freedman,et al. Gastroesophageal Reflux in Relation to Adenocarcinomas of the Esophagus: A Pooled Analysis from the Barrett’s and Esophageal Adenocarcinoma Consortium (BEACON) , 2014, PloS one.
[3] M. Sawyer,et al. Urine Metabolite Analysis Offers Potential Early Diagnosis of Ovarian and Breast Cancers , 2010, Clinical Cancer Research.
[4] J. O’Sullivan,et al. Differential expression of mitochondrial energy metabolism profiles across the metaplasia-dysplasia-adenocarcinoma disease sequence in Barrett's oesophagus. , 2014, Cancer letters.
[5] Oliver Fiehn,et al. Diacetylspermine Is a Novel Prediagnostic Serum Biomarker for Non-Small-Cell Lung Cancer and Has Additive Performance With Pro-Surfactant Protein B. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] A. Allameh,et al. Immunohistochemical analysis of selected molecular markers in esophagus precancerous, adenocarcinoma and squamous cell carcinoma in Iranian subjects. , 2009, Cancer epidemiology.
[7] Mark R Schultz,et al. False discovery rate control is a recommended alternative to Bonferroni-type adjustments in health studies. , 2014, Journal of clinical epidemiology.
[8] Patricia L. Blount,et al. Assessment of Esophageal Adenocarcinoma Risk Using Somatic Chromosome Alterations in Longitudinal Samples in Barrett's Esophagus , 2015, Cancer Prevention Research.
[9] Sarmed S. Sami,et al. Evaluation of a Minimally Invasive Cell Sampling Device Coupled with Assessment of Trefoil Factor 3 Expression for Diagnosing Barrett's Esophagus: A Multi-Center Case–Control Study , 2015, PLoS medicine.
[10] Peter Kraft,et al. Elevated circulating branched chain amino acids are an early event in pancreatic adenocarcinoma development , 2014, Nature Medicine.
[11] Augustin Scalbert,et al. Review of Mass Spectrometry–Based Metabolomics in Cancer Research , 2013, Cancer Epidemiology, Biomarkers & Prevention.
[12] Daniel Raftery,et al. Targeted metabolic profiling of hepatocellular carcinoma and hepatitis C using LC‐MS/MS , 2013, Electrophoresis.
[13] H. Morgenstern,et al. Prediction of Barrett's Esophagus Among Men , 2013, The American Journal of Gastroenterology.
[14] T. Vaughan. From genomics to diagnostics of esophageal adenocarcinoma , 2014, Nature Genetics.
[15] M. Sawyer,et al. Urinary metabolomic signature of esophageal cancer and Barrett’s esophagus , 2012, World Journal of Surgical Oncology.
[16] Thomas M O'Connell,et al. Recent advances in metabolomics in oncology. , 2012, Bioanalysis.
[17] M. Bronner,et al. Central adiposity and risk of Barrett's esophagus. , 2007, Gastroenterology.
[18] Uwe Himmelreich,et al. Pathology of Barrett's esophagus by proton magnetic resonance spectroscopy and a statistical classification strategy. , 2003, American journal of surgery.
[19] D. Raftery,et al. Metabolic profiling: are we en route to better diagnostic tests for cancer? , 2012, Future oncology.
[20] C. Ulrich,et al. Homocysteine, cysteine and risk of incident colorectal cancer in the Women's Health Initiative Observational Cohort , 2011, The American journal of clinical nutrition.
[21] T. Azuma,et al. Metabolome analysis for discovering biomarkers of gastroenterological cancer. , 2014, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
[22] P. Albert,et al. Serum Adiponectin, Leptin, C-Peptide, Homocysteine, and Colorectal Adenoma Recurrence in the Polyp Prevention Trial , 2010, Cancer Epidemiology, Biomarkers & Prevention.
[23] A. D. Jones,et al. Mealtime, Temporal, and Daily Variability of the Human Urinary and Plasma Metabolomes in a Tightly Controlled Environment , 2014, PloS one.
[24] R. Wright,et al. Contribution of uric acid to cancer risk, recurrence, and mortality , 2012, Clinical and Translational Medicine.
[25] B. Puri,et al. In vitro 1H-magnetic resonance spectroscopy of Barrett's esophageal mucosa using magic angle spinning techniques , 2004, European journal of gastroenterology & hepatology.
[26] Wei Zheng,et al. Metabolomics in Epidemiology: Sources of Variability in Metabolite Measurements and Implications , 2013, Cancer Epidemiology, Biomarkers & Prevention.
[27] Martin T. Suchorolski,et al. Warburg and Crabtree Effects in Premalignant Barrett's Esophagus Cell Lines with Active Mitochondria , 2013, PloS one.
[28] G. Hanna,et al. Metabolic profiling detects field effects in nondysplastic tissue from esophageal cancer patients. , 2010, Cancer research.
[29] R. Fitzgerald,et al. Precision prevention of oesophageal adenocarcinoma , 2015, Nature Reviews Gastroenterology &Hepatology.
[30] Jian Zhang,et al. Metabolomics study of esophageal adenocarcinoma. , 2011, The Journal of thoracic and cardiovascular surgery.
[31] J. Hurley,et al. Deregulated Myc requires MondoA/Mlx for metabolic reprogramming and tumorigenesis. , 2015, Cancer cell.
[32] A. Thrift,et al. A Clinical Risk Prediction Model for Barrett Esophagus , 2012, Cancer Prevention Research.
[33] Daniel Raftery,et al. Colorectal cancer detection using targeted serum metabolic profiling. , 2014, Journal of proteome research.
[34] R. Sampliner,et al. Updated guidelines for the diagnosis, surveillance, and therapy of Barrett's esophagus , 2002, American Journal of Gastroenterology.
[35] O. Fiehn,et al. Mass spectrometry-based metabolic profiling reveals different metabolite patterns in invasive ovarian carcinomas and ovarian borderline tumors. , 2006, Cancer research.
[36] Daniel Raftery,et al. Esophageal Cancer Metabolite Biomarkers Detected by LC-MS and NMR Methods , 2012, PloS one.
[37] J. Ajani,et al. Identification of Serum Markers of Esophageal Adenocarcinoma by Global and Targeted Metabolic Profiling. , 2015, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[38] J. Lindon,et al. 'Metabonomics': understanding the metabolic responses of living systems to pathophysiological stimuli via multivariate statistical analysis of biological NMR spectroscopic data. , 1999, Xenobiotica; the fate of foreign compounds in biological systems.
[39] G. Yang,et al. Studies of iron deposits, inducible nitric oxide synthase and nitrotyrosine in a rat model for esophageal adenocarcinoma. , 1998, Carcinogenesis.
[40] Adam A. Margolin,et al. The metabolome regulates the epigenetic landscape during naïve to primed human embryonic stem cell transition , 2015, Nature Cell Biology.
[41] P. Hainaut,et al. Inducible nitric oxide synthase, nitrotyrosine and p53 mutations in the molecular pathogenesis of Barrett's esophagus and esophageal adenocarcinoma , 2008, Molecular carcinogenesis.
[42] D. Raftery,et al. Metabolomics-based methods for early disease diagnostics , 2008, Expert review of molecular diagnostics.
[43] Daniel Raftery,et al. Early detection of recurrent breast cancer using metabolite profiling. , 2010, Cancer research.
[44] G. Hanna,et al. Metabolomic profiling of oesophago-gastric cancer: a systematic review. , 2013, European journal of cancer.
[45] F. Clavel-Chapelon,et al. A prospective study of one‐carbon metabolism biomarkers and cancer of the head and neck and esophagus , 2015, International journal of cancer.
[46] S. Eckhardt,et al. Clinical Applications of Metabolomics in Oncology: A Review , 2009, Clinical Cancer Research.
[47] Patricia L. Blount,et al. Biomarkers in Barrett's esophagus. , 2003, Gastrointestinal endoscopy clinics of North America.
[48] B. Reid,et al. Barrett's oesophagus and oesophageal adenocarcinoma: time for a new synthesis , 2010, Nature Reviews Cancer.
[49] L. Kolonel,et al. Relationship of serum uric acid to cancer occurrence in a prospective male cohort. , 1994, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.
[50] Kenneth K Wang,et al. Updated Guidelines 2008 for the Diagnosis, Surveillance and Therapy of Barrett's Esophagus , 1998, The American Journal of Gastroenterology.
[51] A. Thrift,et al. A model to determine absolute risk for esophageal adenocarcinoma. , 2013, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[52] J. Lagergren,et al. A model for predicting individuals’ absolute risk of esophageal adenocarcinoma: Moving toward tailored screening and prevention , 2016, International journal of cancer.
[53] Á. Lanas,et al. Free radicals and antioxidant systems in reflux esophagitis and Barrett's esophagus. , 2005, World journal of gastroenterology.
[54] Antonio Gasbarrini,et al. Homocysteine Triggers Mucosal Microvascular Activation in Inflammatory Bowel Disease , 2005, The American Journal of Gastroenterology.
[55] P. Malfertheiner,et al. Gastroesophageal reflux disease—from reflux episodes to mucosal inflammation , 2012, Nature Reviews Gastroenterology &Hepatology.
[56] J. Klenk,et al. Use of penalized splines in extended Cox-type additive hazard regression to flexibly estimate the effect of time-varying serum uric acid on risk of cancer incidence: a prospective, population-based study in 78,850 men. , 2009, Annals of epidemiology.
[57] Rebecca C Fitzgerald,et al. Ordering of mutations in preinvasive disease stages of esophageal carcinogenesis , 2014, Nature Genetics.
[58] D. Raftery,et al. Targeted serum metabolite profiling of nucleosides in esophageal adenocarcinoma. , 2010, Rapid communications in mass spectrometry : RCM.
[59] John T. Wei,et al. Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression , 2009, Nature.
[60] R. Austin,et al. Contributions of hyperhomocysteinemia to atherosclerosis: Causal relationship and potential mechanisms , 2009, BioFactors.
[61] Trevor Hastie,et al. Regularization Paths for Generalized Linear Models via Coordinate Descent. , 2010, Journal of statistical software.
[62] Thomas Lengauer,et al. ROCR: visualizing classifier performance in R , 2005, Bioinform..